Revenues and things to come...
Recap from previous news releases:
1- Baseline revenues in 2014 to nearly double - more orderes will be announced and we will approach 40 million in revenues;
2- PBI 4050 phase 1b /II to commence H2;
3-IVIG/Plasminogen trials to commence H2;
4- 2 new orphan drugs to be announced in H2;
5- New partnerships to be announced - new plants etc?
Why are people selling given that this company is firing on all cyclinders? I still believe there is some manipulation going on.. I am personally buying more as this is a once in a life time opportunity where the risk/reward is amazing... low risk and high outcome...
Any other catalysts that i am missing?